Loading…
LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
Abstract INTRODUCTION The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with gr...
Saved in:
| Published in: | Neuro-oncology (Charlottesville, Va.) Va.), 2023-11, Vol.25 (Supplement_5), p.v310-v311 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c1332-e4120f0e8b0ae0067924ac6949cecef8a99229e454e7eec00b4beeaa19a7449f3 |
|---|---|
| cites | |
| container_end_page | v311 |
| container_issue | Supplement_5 |
| container_start_page | v310 |
| container_title | Neuro-oncology (Charlottesville, Va.) |
| container_volume | 25 |
| creator | Wen, Patrick Mellinghoff, Ingo van den Bent, Martin Blumenthal, Deborah Touat, Mehdi Peters, Katherine Clarke, Jennifer Mendez, Joe Yust-Katz, Shlomit Mason, Warren Ducray, Francois Umemura, Yoshie Nabors, L Burt Holdhoff, Matthias Hottinger, Andreas Arakawa, Yoshiki Sepúlveda, Juan Wick, Wolfgang Soffietti, Riccardo Perry, James Giglio, Pierre de la Fuente, Macarena Maher, Elizabeth Zhao, Dan Pandya, Shuchi Steelman, Lori Hassan, Islam Cloughesy, Timothy Ellingson, Benjamin |
| description | Abstract
INTRODUCTION
The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with grade 2 mIDH1/2 glioma previously treated with surgery only. Given the limitations of traditional bi-dimensional measurements, evaluating volumetry and tumor growth rate (TGR) is an additional method of measuring treatment effect in these diffuse growing tumors.
METHODS
Magnetic resonance imaging (MRI) scans were performed at baseline and every 12 weeks on-treatment; up to three pre-treatment MRI scans were requested when available. Tumor volumes were derived per blinded independent review committee using a semi-automated approach. TGR was defined as percentage change in tumor volume every 6 months. Patients with evaluable baseline and ≥ 1 MRI during the corresponding period were included in the analysis. The difference in TGR in each arm was assessed by slope of tumor growth over time using a linear mixed model.
RESULTS
331 patients were randomized to vorasidenib (n=168) or placebo (n=163). Median follow-up was 14.2 months. On-treatment TGR was −2.5% (95% CI, −4.7, −0.2) with vorasidenib (n=167) and 13.9% (95% CI, 11.1, 16.8) with placebo (n=161). In patients with available imaging data, TGR pre- and post-treatment with vorasidenib (n=56) was 13.2% (95% CI, 10.3, 16.3) and −3.3% (95% CI, −5.2, −1.2), respectively, while placebo (n=67) was 18.3% (95% CI, 15.0, 21.7) and 12.2% (95% CI, 9.5, 14.9), respectively. In patients who crossed over from placebo with available imaging data (n=38), TGR pre- and post-crossover was 22.4% (95% CI, 15.7, 29.4) and 5.2% (95% CI, −3.8, 15.0), respectively.
CONCLUSIONS
Tumor growth was observed in patients with mIDH1/2 gliomas before receiving vorasidenib or placebo. Treatment with vorasidenib reduced the TGR and shrunk tumor volume, whereas continued growth in tumor volume was observed in patients receiving placebo. |
| doi_str_mv | 10.1093/neuonc/noad179.1202 |
| format | article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noad179_1202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noad179.1202</oup_id><sourcerecordid>10.1093/neuonc/noad179.1202</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1332-e4120f0e8b0ae0067924ac6949cecef8a99229e454e7eec00b4beeaa19a7449f3</originalsourceid><addsrcrecordid>eNqNUM1OhDAYJEYTdfUJvPQBhG3Lb72VpUAj0A0UjV5IF0ui0WUD2YOP45vadfcBPM3MN5lJvrGsOwQdBIm73Or9uO2X21G9oZA4CEN8Zl0hH7u2HwXB-R_HduSj8NK6nucPCDHyA3Rl_RQyfrRh4ABerulKApGCJ1HThies4jGQNaOyZJUxKlC2khrGkxwBUR8Qg4SnadswkBVclBTItjROVotnmYOaSvYAata0hWxAWosSyJyZc5WIkr-y5B4koo0LZscFr4xa59RUucAIngnQyDZ5ubEuBvU569sTLqw2ZXKV24XI-IoWdo9cF9vaM18PUEcbqDSEQUiwp_qAeKTXvR4iRQjGRHu-p0Otewg33kZrpRBRoeeRwV1Y7rG3n8Z5nvTQ7ab3LzV9dwh2h5W748rdaeXusLJJOcfUuN_9K_ALol92CQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY</title><source>Oxford Journals Online</source><creator>Wen, Patrick ; Mellinghoff, Ingo ; van den Bent, Martin ; Blumenthal, Deborah ; Touat, Mehdi ; Peters, Katherine ; Clarke, Jennifer ; Mendez, Joe ; Yust-Katz, Shlomit ; Mason, Warren ; Ducray, Francois ; Umemura, Yoshie ; Nabors, L Burt ; Holdhoff, Matthias ; Hottinger, Andreas ; Arakawa, Yoshiki ; Sepúlveda, Juan ; Wick, Wolfgang ; Soffietti, Riccardo ; Perry, James ; Giglio, Pierre ; de la Fuente, Macarena ; Maher, Elizabeth ; Zhao, Dan ; Pandya, Shuchi ; Steelman, Lori ; Hassan, Islam ; Cloughesy, Timothy ; Ellingson, Benjamin</creator><creatorcontrib>Wen, Patrick ; Mellinghoff, Ingo ; van den Bent, Martin ; Blumenthal, Deborah ; Touat, Mehdi ; Peters, Katherine ; Clarke, Jennifer ; Mendez, Joe ; Yust-Katz, Shlomit ; Mason, Warren ; Ducray, Francois ; Umemura, Yoshie ; Nabors, L Burt ; Holdhoff, Matthias ; Hottinger, Andreas ; Arakawa, Yoshiki ; Sepúlveda, Juan ; Wick, Wolfgang ; Soffietti, Riccardo ; Perry, James ; Giglio, Pierre ; de la Fuente, Macarena ; Maher, Elizabeth ; Zhao, Dan ; Pandya, Shuchi ; Steelman, Lori ; Hassan, Islam ; Cloughesy, Timothy ; Ellingson, Benjamin</creatorcontrib><description>Abstract
INTRODUCTION
The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with grade 2 mIDH1/2 glioma previously treated with surgery only. Given the limitations of traditional bi-dimensional measurements, evaluating volumetry and tumor growth rate (TGR) is an additional method of measuring treatment effect in these diffuse growing tumors.
METHODS
Magnetic resonance imaging (MRI) scans were performed at baseline and every 12 weeks on-treatment; up to three pre-treatment MRI scans were requested when available. Tumor volumes were derived per blinded independent review committee using a semi-automated approach. TGR was defined as percentage change in tumor volume every 6 months. Patients with evaluable baseline and ≥ 1 MRI during the corresponding period were included in the analysis. The difference in TGR in each arm was assessed by slope of tumor growth over time using a linear mixed model.
RESULTS
331 patients were randomized to vorasidenib (n=168) or placebo (n=163). Median follow-up was 14.2 months. On-treatment TGR was −2.5% (95% CI, −4.7, −0.2) with vorasidenib (n=167) and 13.9% (95% CI, 11.1, 16.8) with placebo (n=161). In patients with available imaging data, TGR pre- and post-treatment with vorasidenib (n=56) was 13.2% (95% CI, 10.3, 16.3) and −3.3% (95% CI, −5.2, −1.2), respectively, while placebo (n=67) was 18.3% (95% CI, 15.0, 21.7) and 12.2% (95% CI, 9.5, 14.9), respectively. In patients who crossed over from placebo with available imaging data (n=38), TGR pre- and post-crossover was 22.4% (95% CI, 15.7, 29.4) and 5.2% (95% CI, −3.8, 15.0), respectively.
CONCLUSIONS
Tumor growth was observed in patients with mIDH1/2 gliomas before receiving vorasidenib or placebo. Treatment with vorasidenib reduced the TGR and shrunk tumor volume, whereas continued growth in tumor volume was observed in patients receiving placebo.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noad179.1202</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v310-v311</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1332-e4120f0e8b0ae0067924ac6949cecef8a99229e454e7eec00b4beeaa19a7449f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Wen, Patrick</creatorcontrib><creatorcontrib>Mellinghoff, Ingo</creatorcontrib><creatorcontrib>van den Bent, Martin</creatorcontrib><creatorcontrib>Blumenthal, Deborah</creatorcontrib><creatorcontrib>Touat, Mehdi</creatorcontrib><creatorcontrib>Peters, Katherine</creatorcontrib><creatorcontrib>Clarke, Jennifer</creatorcontrib><creatorcontrib>Mendez, Joe</creatorcontrib><creatorcontrib>Yust-Katz, Shlomit</creatorcontrib><creatorcontrib>Mason, Warren</creatorcontrib><creatorcontrib>Ducray, Francois</creatorcontrib><creatorcontrib>Umemura, Yoshie</creatorcontrib><creatorcontrib>Nabors, L Burt</creatorcontrib><creatorcontrib>Holdhoff, Matthias</creatorcontrib><creatorcontrib>Hottinger, Andreas</creatorcontrib><creatorcontrib>Arakawa, Yoshiki</creatorcontrib><creatorcontrib>Sepúlveda, Juan</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Soffietti, Riccardo</creatorcontrib><creatorcontrib>Perry, James</creatorcontrib><creatorcontrib>Giglio, Pierre</creatorcontrib><creatorcontrib>de la Fuente, Macarena</creatorcontrib><creatorcontrib>Maher, Elizabeth</creatorcontrib><creatorcontrib>Zhao, Dan</creatorcontrib><creatorcontrib>Pandya, Shuchi</creatorcontrib><creatorcontrib>Steelman, Lori</creatorcontrib><creatorcontrib>Hassan, Islam</creatorcontrib><creatorcontrib>Cloughesy, Timothy</creatorcontrib><creatorcontrib>Ellingson, Benjamin</creatorcontrib><title>LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract
INTRODUCTION
The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with grade 2 mIDH1/2 glioma previously treated with surgery only. Given the limitations of traditional bi-dimensional measurements, evaluating volumetry and tumor growth rate (TGR) is an additional method of measuring treatment effect in these diffuse growing tumors.
METHODS
Magnetic resonance imaging (MRI) scans were performed at baseline and every 12 weeks on-treatment; up to three pre-treatment MRI scans were requested when available. Tumor volumes were derived per blinded independent review committee using a semi-automated approach. TGR was defined as percentage change in tumor volume every 6 months. Patients with evaluable baseline and ≥ 1 MRI during the corresponding period were included in the analysis. The difference in TGR in each arm was assessed by slope of tumor growth over time using a linear mixed model.
RESULTS
331 patients were randomized to vorasidenib (n=168) or placebo (n=163). Median follow-up was 14.2 months. On-treatment TGR was −2.5% (95% CI, −4.7, −0.2) with vorasidenib (n=167) and 13.9% (95% CI, 11.1, 16.8) with placebo (n=161). In patients with available imaging data, TGR pre- and post-treatment with vorasidenib (n=56) was 13.2% (95% CI, 10.3, 16.3) and −3.3% (95% CI, −5.2, −1.2), respectively, while placebo (n=67) was 18.3% (95% CI, 15.0, 21.7) and 12.2% (95% CI, 9.5, 14.9), respectively. In patients who crossed over from placebo with available imaging data (n=38), TGR pre- and post-crossover was 22.4% (95% CI, 15.7, 29.4) and 5.2% (95% CI, −3.8, 15.0), respectively.
CONCLUSIONS
Tumor growth was observed in patients with mIDH1/2 gliomas before receiving vorasidenib or placebo. Treatment with vorasidenib reduced the TGR and shrunk tumor volume, whereas continued growth in tumor volume was observed in patients receiving placebo.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNUM1OhDAYJEYTdfUJvPQBhG3Lb72VpUAj0A0UjV5IF0ui0WUD2YOP45vadfcBPM3MN5lJvrGsOwQdBIm73Or9uO2X21G9oZA4CEN8Zl0hH7u2HwXB-R_HduSj8NK6nucPCDHyA3Rl_RQyfrRh4ABerulKApGCJ1HThies4jGQNaOyZJUxKlC2khrGkxwBUR8Qg4SnadswkBVclBTItjROVotnmYOaSvYAata0hWxAWosSyJyZc5WIkr-y5B4koo0LZscFr4xa59RUucAIngnQyDZ5ubEuBvU569sTLqw2ZXKV24XI-IoWdo9cF9vaM18PUEcbqDSEQUiwp_qAeKTXvR4iRQjGRHu-p0Otewg33kZrpRBRoeeRwV1Y7rG3n8Z5nvTQ7ab3LzV9dwh2h5W748rdaeXusLJJOcfUuN_9K_ALol92CQ</recordid><startdate>20231110</startdate><enddate>20231110</enddate><creator>Wen, Patrick</creator><creator>Mellinghoff, Ingo</creator><creator>van den Bent, Martin</creator><creator>Blumenthal, Deborah</creator><creator>Touat, Mehdi</creator><creator>Peters, Katherine</creator><creator>Clarke, Jennifer</creator><creator>Mendez, Joe</creator><creator>Yust-Katz, Shlomit</creator><creator>Mason, Warren</creator><creator>Ducray, Francois</creator><creator>Umemura, Yoshie</creator><creator>Nabors, L Burt</creator><creator>Holdhoff, Matthias</creator><creator>Hottinger, Andreas</creator><creator>Arakawa, Yoshiki</creator><creator>Sepúlveda, Juan</creator><creator>Wick, Wolfgang</creator><creator>Soffietti, Riccardo</creator><creator>Perry, James</creator><creator>Giglio, Pierre</creator><creator>de la Fuente, Macarena</creator><creator>Maher, Elizabeth</creator><creator>Zhao, Dan</creator><creator>Pandya, Shuchi</creator><creator>Steelman, Lori</creator><creator>Hassan, Islam</creator><creator>Cloughesy, Timothy</creator><creator>Ellingson, Benjamin</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231110</creationdate><title>LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY</title><author>Wen, Patrick ; Mellinghoff, Ingo ; van den Bent, Martin ; Blumenthal, Deborah ; Touat, Mehdi ; Peters, Katherine ; Clarke, Jennifer ; Mendez, Joe ; Yust-Katz, Shlomit ; Mason, Warren ; Ducray, Francois ; Umemura, Yoshie ; Nabors, L Burt ; Holdhoff, Matthias ; Hottinger, Andreas ; Arakawa, Yoshiki ; Sepúlveda, Juan ; Wick, Wolfgang ; Soffietti, Riccardo ; Perry, James ; Giglio, Pierre ; de la Fuente, Macarena ; Maher, Elizabeth ; Zhao, Dan ; Pandya, Shuchi ; Steelman, Lori ; Hassan, Islam ; Cloughesy, Timothy ; Ellingson, Benjamin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1332-e4120f0e8b0ae0067924ac6949cecef8a99229e454e7eec00b4beeaa19a7449f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wen, Patrick</creatorcontrib><creatorcontrib>Mellinghoff, Ingo</creatorcontrib><creatorcontrib>van den Bent, Martin</creatorcontrib><creatorcontrib>Blumenthal, Deborah</creatorcontrib><creatorcontrib>Touat, Mehdi</creatorcontrib><creatorcontrib>Peters, Katherine</creatorcontrib><creatorcontrib>Clarke, Jennifer</creatorcontrib><creatorcontrib>Mendez, Joe</creatorcontrib><creatorcontrib>Yust-Katz, Shlomit</creatorcontrib><creatorcontrib>Mason, Warren</creatorcontrib><creatorcontrib>Ducray, Francois</creatorcontrib><creatorcontrib>Umemura, Yoshie</creatorcontrib><creatorcontrib>Nabors, L Burt</creatorcontrib><creatorcontrib>Holdhoff, Matthias</creatorcontrib><creatorcontrib>Hottinger, Andreas</creatorcontrib><creatorcontrib>Arakawa, Yoshiki</creatorcontrib><creatorcontrib>Sepúlveda, Juan</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Soffietti, Riccardo</creatorcontrib><creatorcontrib>Perry, James</creatorcontrib><creatorcontrib>Giglio, Pierre</creatorcontrib><creatorcontrib>de la Fuente, Macarena</creatorcontrib><creatorcontrib>Maher, Elizabeth</creatorcontrib><creatorcontrib>Zhao, Dan</creatorcontrib><creatorcontrib>Pandya, Shuchi</creatorcontrib><creatorcontrib>Steelman, Lori</creatorcontrib><creatorcontrib>Hassan, Islam</creatorcontrib><creatorcontrib>Cloughesy, Timothy</creatorcontrib><creatorcontrib>Ellingson, Benjamin</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wen, Patrick</au><au>Mellinghoff, Ingo</au><au>van den Bent, Martin</au><au>Blumenthal, Deborah</au><au>Touat, Mehdi</au><au>Peters, Katherine</au><au>Clarke, Jennifer</au><au>Mendez, Joe</au><au>Yust-Katz, Shlomit</au><au>Mason, Warren</au><au>Ducray, Francois</au><au>Umemura, Yoshie</au><au>Nabors, L Burt</au><au>Holdhoff, Matthias</au><au>Hottinger, Andreas</au><au>Arakawa, Yoshiki</au><au>Sepúlveda, Juan</au><au>Wick, Wolfgang</au><au>Soffietti, Riccardo</au><au>Perry, James</au><au>Giglio, Pierre</au><au>de la Fuente, Macarena</au><au>Maher, Elizabeth</au><au>Zhao, Dan</au><au>Pandya, Shuchi</au><au>Steelman, Lori</au><au>Hassan, Islam</au><au>Cloughesy, Timothy</au><au>Ellingson, Benjamin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2023-11-10</date><risdate>2023</risdate><volume>25</volume><issue>Supplement_5</issue><spage>v310</spage><epage>v311</epage><pages>v310-v311</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract
INTRODUCTION
The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with grade 2 mIDH1/2 glioma previously treated with surgery only. Given the limitations of traditional bi-dimensional measurements, evaluating volumetry and tumor growth rate (TGR) is an additional method of measuring treatment effect in these diffuse growing tumors.
METHODS
Magnetic resonance imaging (MRI) scans were performed at baseline and every 12 weeks on-treatment; up to three pre-treatment MRI scans were requested when available. Tumor volumes were derived per blinded independent review committee using a semi-automated approach. TGR was defined as percentage change in tumor volume every 6 months. Patients with evaluable baseline and ≥ 1 MRI during the corresponding period were included in the analysis. The difference in TGR in each arm was assessed by slope of tumor growth over time using a linear mixed model.
RESULTS
331 patients were randomized to vorasidenib (n=168) or placebo (n=163). Median follow-up was 14.2 months. On-treatment TGR was −2.5% (95% CI, −4.7, −0.2) with vorasidenib (n=167) and 13.9% (95% CI, 11.1, 16.8) with placebo (n=161). In patients with available imaging data, TGR pre- and post-treatment with vorasidenib (n=56) was 13.2% (95% CI, 10.3, 16.3) and −3.3% (95% CI, −5.2, −1.2), respectively, while placebo (n=67) was 18.3% (95% CI, 15.0, 21.7) and 12.2% (95% CI, 9.5, 14.9), respectively. In patients who crossed over from placebo with available imaging data (n=38), TGR pre- and post-crossover was 22.4% (95% CI, 15.7, 29.4) and 5.2% (95% CI, −3.8, 15.0), respectively.
CONCLUSIONS
Tumor growth was observed in patients with mIDH1/2 gliomas before receiving vorasidenib or placebo. Treatment with vorasidenib reduced the TGR and shrunk tumor volume, whereas continued growth in tumor volume was observed in patients receiving placebo.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noad179.1202</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8517 |
| ispartof | Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v310-v311 |
| issn | 1522-8517 1523-5866 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_neuonc_noad179_1202 |
| source | Oxford Journals Online |
| title | LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A37%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LTBK-06.%20IMPACT%20OF%20VORASIDENIB%20TREATMENT%20ON%20MUTANT%20IDH1%20OR%20IDH2%20DIFFUSE%20GLIOMA%20TUMOR%20GROWTH%20RATE:%20RESULTS%20FROM%20THE%20RANDOMIZED,%20DOUBLE-BLIND,%20PHASE%203%20INDIGO%20STUDY&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Wen,%20Patrick&rft.date=2023-11-10&rft.volume=25&rft.issue=Supplement_5&rft.spage=v310&rft.epage=v311&rft.pages=v310-v311&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noad179.1202&rft_dat=%3Coup_cross%3E10.1093/neuonc/noad179.1202%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1332-e4120f0e8b0ae0067924ac6949cecef8a99229e454e7eec00b4beeaa19a7449f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noad179.1202&rfr_iscdi=true |